A Phase 3 Randomized Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Hepatocellular Carcinoma
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1. Patients must have a first diagnosis of Hepatocellular Carcinoma (HCC) amenable for management with curative intent by resection or local ablation. 2. Patients must have undergone Hepatic resection 3. Patients must have complete resection documented or must have achieved radiologically documented complete response
You may not be eligible for this study if the following are true:
-
1. Prior recurrence of Hepatocellular Carcinoma (HCC) 2. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC 3. Any evidence of tumor metastasis or co-existing malignant disease.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.